Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMEPAN timing of chemotherapy in asymptomatic metastatic pancreatic cancer
NL-OMON52527Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of folinic acid, fluorouracil, oxaliplatin, irinotecan, gemcitabine and 1 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Quality-adjusted survival. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
folinic acidfluorouraciloxaliplatinirinotecangemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON52527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52527.